Overview

LL-37


'LL-37' can also refer to...

LL-37

Endogenous antimicrobial peptide LL-37 induces human vasodilatation †

Glycosaminoglycans inhibit the antibacterial activity of LL-37 in biological fluids

LEAP-2, LL-37 and RNase7 in tonsillar tissue: downregulated expression in seasonal allergic rhinitis

Role of uropathogenic Escherichia coli OmpT in the resistance against human cathelicidin LL-37

The anti-microbial peptide LL-37 inhibits the activation of dendritic cells by TLR ligands

Succesful Immunotherapy of established lesions induced by high risk HPV (LL3-7) Chairperson: Toshimitsu Uede

Increased resistance to cationic antimicrobial peptide LL-37 in methicillin-resistant strains of Staphylococcus aureus

Low concentrations of LL-37 alter IL-8 production by keratinocytes and bronchial epithelial cells in response to proinflammatory stimuli

Bacterial products increase expression of the human cathelicidin hCAP-18/LL-37 in cultured human sinus epithelial cells

Human anti-microbial cathelicidin peptide LL-37 suppresses the LPS-induced apoptosis of endothelial cells

Antimicrobial cathelicidin peptide LL-37 inhibits the pyroptosis of macrophages and improves the survival of polybacterial septic mice

Antibacterial activity of the human host defence peptide LL-37 and selected synthetic cationic lipids against bacteria associated with oral and upper respiratory tract infections

Susceptibilities of periodontopathogenic and cariogenic bacteria to antibacterial peptides, β-defensins and LL37, produced by human epithelial cells

Salivary mucins inhibit antibacterial activity of the cathelicidin-derived LL-37 peptide but not the cationic steroid CSA-13

 

More Like This

Show all results sharing this subject:

  • Medicine and Health

GO

Show Summary Details

Quick Reference

Human cathelicidin, found in leucocytes, particularly neutrophils, and up-regulated in inflammation.

Subjects: Medicine and Health.


Reference entries

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.